SG161255A1 - Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof - Google Patents

Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof

Info

Publication number
SG161255A1
SG161255A1 SG201002461-0A SG2010024610A SG161255A1 SG 161255 A1 SG161255 A1 SG 161255A1 SG 2010024610 A SG2010024610 A SG 2010024610A SG 161255 A1 SG161255 A1 SG 161255A1
Authority
SG
Singapore
Prior art keywords
viral
variants
virus
present
agents
Prior art date
Application number
SG201002461-0A
Other languages
English (en)
Inventor
Angeline Ingrid Bartholomeusz
Stephen Locarnini
Anna Ayres
Margaret Littlejohn
Paul Desmond
Peter William Angus
Original Assignee
Melbourne Health
St Vincentaes Hospital Melbour
Austin Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005901757A external-priority patent/AU2005901757A0/en
Application filed by Melbourne Health, St Vincentaes Hospital Melbour, Austin Health filed Critical Melbourne Health
Publication of SG161255A1 publication Critical patent/SG161255A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
SG201002461-0A 2005-04-08 2006-04-04 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof SG161255A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005901757A AU2005901757A0 (en) 2005-04-08 Viral resistant mutants and uses thereof
AU2005903972A AU2005903972A0 (en) 2005-07-26 Viral resistant mutants and uses thereof

Publications (1)

Publication Number Publication Date
SG161255A1 true SG161255A1 (en) 2010-05-27

Family

ID=37073018

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201002461-0A SG161255A1 (en) 2005-04-08 2006-04-04 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof

Country Status (6)

Country Link
US (3) US7887813B2 (fr)
EP (1) EP1874923A4 (fr)
JP (2) JP2008534020A (fr)
NZ (1) NZ562284A (fr)
SG (1) SG161255A1 (fr)
WO (1) WO2006105597A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO351996A0 (en) * 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
US7405039B2 (en) * 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP2033967A1 (fr) 2002-04-12 2009-03-11 Melbourne Health Variantes de l'hépatite B virale avec une susceptibilité réduite aux analogues nucléosides et utilisations associées
EP1874923A4 (fr) * 2005-04-08 2010-08-04 Melbourne Health Variantes du virus de l'hépatite b présentant une résistance aux agents de nucléotide anti-virale et application de ces variantes
AU2006230802A1 (en) * 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
EP1948800B1 (fr) 2005-10-21 2015-12-23 Melbourne Health Mutants ayant une résistance aux agents antiviraux et applications de ceux-ci
US8859198B2 (en) 2006-06-06 2014-10-14 Abl Sa Detection and use of antiviral resistance mutations
SG189280A1 (en) * 2010-10-07 2013-05-31 Agency Science Tech & Res Parp-1 inhibitors
US20220305107A1 (en) * 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237053A (en) 1986-06-24 1993-08-17 Immuno Aktiengesellschaft Preparation active against Pseudomonas aeruginosa infections and methods of producing them
AT391080B (de) 1986-06-24 1990-08-10 Immuno Ag Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
WO1990006696A2 (fr) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Vaccin meningocoque de la proteine de la membrane externe de la classe 1
US6100380A (en) 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
WO1993024636A1 (fr) 1992-05-29 1993-12-09 The University Of British Columbia Emploi de la proteine oprf dans l'expression d'oligopeptides a la surface de cellules bacteriennes
US5595739A (en) 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
ATE190657T1 (de) 1994-12-16 2000-04-15 Chiron Behring Gmbh & Co Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa
CA2175435A1 (fr) 1996-04-30 1997-10-31 Joseph Lam Proteines intervenant dans la synthese et la fixation de l'antigene o chez pseudomonas aeruginosa
AU734831C (en) 1996-11-08 2002-05-09 Melbourne Health Viral variants and methods for detecting same
AUPO351996A0 (en) 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
US6436391B1 (en) 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
EP1257661A1 (fr) * 2000-02-03 2002-11-20 Melbourne Health Test de detection de virus d'hepatite b variants montrant une reponse deficiente aux agents
AUPQ810900A0 (en) 2000-06-09 2000-07-06 Austin and Repatriation Medical Centre, The Viral variants and methods of using same
CA2309379A1 (fr) * 2000-06-09 2001-12-09 Thomas Bock Variants viraux et utilisations connexes
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
CA2475446C (fr) * 2002-02-07 2014-05-06 Melbourne Health Variants viraux presentant une sensibilite modifiee par rapport aux analogues nucleosidiques et leurs applications
EP2033967A1 (fr) 2002-04-12 2009-03-11 Melbourne Health Variantes de l'hépatite B virale avec une susceptibilité réduite aux analogues nucléosides et utilisations associées
AU2003279103A1 (en) 2002-10-01 2004-04-23 Gilead Sciences, Inc. Hbv mutations associated with reduced susceptibility to adefovir
AU2003902983A0 (en) * 2003-06-13 2003-06-26 Angeline Ingrid Bartholomeusz Viral polymerase and modulation thereof
AU2004285983B2 (en) * 2003-10-21 2012-06-28 Alfred Health HBV variants detection and application
ATE503830T1 (de) * 2004-09-28 2011-04-15 Melbourne Health Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon
EP1858915B1 (fr) 2005-03-15 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Variantes du virus de l hepatite b resistant a certains analogues de nucleosides, mais sensibles a d'autres, et utilisations de ces variantes
PL1858916T4 (pl) 2005-03-15 2015-04-30 Fujirebio Europe N V Warianty wirusa zapalenia wątroby typu b z obniżoną wrażliwością na analogi nukleozydów i ich zastosowanie
AU2006230802A1 (en) 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
EP1874923A4 (fr) 2005-04-08 2010-08-04 Melbourne Health Variantes du virus de l'hépatite b présentant une résistance aux agents de nucléotide anti-virale et application de ces variantes
US8859198B2 (en) 2006-06-06 2014-10-14 Abl Sa Detection and use of antiviral resistance mutations

Also Published As

Publication number Publication date
US20140199268A1 (en) 2014-07-17
WO2006105597A8 (fr) 2007-05-10
EP1874923A1 (fr) 2008-01-09
US20110236422A1 (en) 2011-09-29
WO2006105597A1 (fr) 2006-10-12
US9701982B2 (en) 2017-07-11
EP1874923A4 (fr) 2010-08-04
US8367317B2 (en) 2013-02-05
US20080176218A1 (en) 2008-07-24
JP2013151496A (ja) 2013-08-08
JP2008534020A (ja) 2008-08-28
NZ562284A (en) 2010-02-26
US7887813B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
SG161255A1 (en) Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
EP1799814A4 (fr) Variants du virus de l'hépatite b présentant une résistance à des agents nucléosidiques antiviraux et leurs applications
EP1476543A4 (fr) Variants viraux presentant une sensibilite modifiee par rapport aux analogues nucleosidiques et leurs applications
Klebanoff et al. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost‐effectiveness analysis
Ning et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)
Burns et al. Viral hepatitis B: clinical and epidemiological characteristics
Hatzakis et al. HBV virological assessment
EP2404933A3 (fr) Détection de variantes d'HBV et application
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
Jang et al. Chronic hepatitis C
WO2009039246A3 (fr) Procédés de traitement d'une infection par un virus de la famille des flaviviridae, compositions pour traiter une infection par un virus de la famille des flaviviridae, et tests d'identification par criblage des compositions pour traiter une infection par un virus de la famille des flaviviridae
MX2009005942A (es) Anticuerpos recombinantes contra el virus de hepatitis c y metodos para obtener y usar los mismos.
Schulte et al. Characterization of CD8+ T-cell response in acute and resolved hepatitis A virus infection
PT1858915E (pt) Variantes do vírus de hepatite b resistentes contra alguns análogos de nucleósido, mas sensíveis a outros, e suas utilizações
Mixson-Hayden et al. Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users
HK1053144A1 (en) Hepatitis b virus dna polymerase and surface antigen variants and methods of using same
EP2360257A3 (fr) Variantes du virus de l'hépatite B (HBV)
Ye et al. High-frequency notable HBV mutations identified in blood donors with occult hepatitis B infection from heyuan city of southern China
WO2007059348A3 (fr) Compositions et procedes pour la detection d'un sous-type du hcv-1
Berzsenyi et al. GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease
TW200722527A (en) Methods of detecting hepatitis C virus
Koshiol et al. Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention
Hsieh et al. The commercial dengue NS1 antigen-capture ELISA may be superior to IgM detection, virus isolation and RT-PCR for rapid laboratory diagnosis of acute dengue infection based on a single serum sample
Syed et al. Identification of rare hepatitis C virus genotype 5a among Indian population
Zaki et al. Prevalence of hepatitis E virus among hemodialysis patients: one Egyptian Center Study